Macular Hemorrhage in the Aging Eye:The Effects of Anticoagulants
NEJM 318:1126-1127, Kingham,J.D.,et al, 1988
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Blurred Vision
BMJ 368:m569, Zhou, S.,et al, 2020
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Delusions and Hallucinations in Dementia with Lewy Bodies: Worsening with Memantine
Neurol 65:481-482, Ridha,B.H.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Subacute Meningoencephalitis in a Subset of Patients with AD After AB42 Immunization
Neurol 61:46-54,7, Orgogozo,J.M.,et al, 2003
Dementia with Lewy Bodies
Lancet 362:1689-1690, Wilcock,G.K., 2003
Severe Worsening of Parkinsonism in Lewy Body Dementia Due to Donepezil
Neurol 61:1452, Onofri,M. & Thomas,A., 2003
A Double-blind Placebo-controlled Trial of Topiramate Treatment for Essential Tremor
Neurol 59:132-134, Connor,G.S., 2002
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Diagnosing Dementia with Lewy Bodies
Lancet 354:1227-1228, McKeith,I.G.,et al, 1999
Ginkgo Biloba for Dementia
The Medical Letter 40:63-64, , 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
Low Blood Pressure and Dementia in Elderly People:The Kungsholmen Project
BMJ 312:805-808, 7931996., Guo,Z.,et al, 1996
Is the Cognitive Function of Older Pts Affected by Antihypertensive Treatment? Med Res Council's Treat Trial
BMJ 312:801-805, 7931996., Prince,M.J.,et al, 1996
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Effectiveness & Safety of Velnacrine for Treatment of Alzheimer's Disease:A Double Blind, Placebo-Controlled Study
Arch Int Med 155:1766-1772, Antuono,P.G.,et al, 1995
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
Botulinum Toxin Treatment of Tremors
Neurol 41:1185-1188, Jankovic,J.&Schwartz,K., 1991